Try our mobile app

Switch to company model in classical logic    *

General information

Country: BRITAIN

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

AstraZeneca PLC operates as a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.
Website: astrazeneca.com



Growth: Good revenue growth rate 55.6%, there is acceleration compared to average historical growth rates 24.0%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -16.7%

Profitability: LTM EBITDA margin is positive, +17.0%. On average the margin is decreasing unsteadily. Gross margin is high, +69.2%. In the last quarter the company did not beat the estimated EPS, -10.3%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.9%. Free cash flow yield -1.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 177.3% higher than minimum and 13.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.8x by EV / Sales multiple , the company can be 70.9% overvalued

Insiders: For the last 3 months insiders sold company shares on $2.2 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: AZN
Share price, USD:  (+0.6%)169.26
year average price 106.86  


year start price 72.66 2025-07-26

min close price 71.83 2025-07-28

max close price 195.15 2026-07-03

current price 169.26 2026-07-25
Common stocks: 3 104 549 822

Dividend Yield:  0.9%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 77.6x
EV / EBITDA annualized: 62.4x
Last revenue growth (y/y):  +55.6%
Last growth of EBITDA (y/y):  -18.4%
Historical revenue growth:  +24.0%
Historical growth of EBITDA:  +1.8%
EV / Sales: 13.2x
Margin (EBITDA LTM / Revenue): 17.0%
Fundamental value created in LTM:
Market Cap ($m): 522 403
Net Debt ($m): 25 337
EV (Enterprise Value): 547 740
Price to Book: 11.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05zacks.com

AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?

2026-02-04zacks.com

FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway

2026-02-03zacks.com

Why Astrazeneca (AZN) Dipped More Than Broader Market Today

2026-02-03wsj.com

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

2026-02-02proactiveinvestors.co.uk

AstraZeneca begins trading directly on the NYSE

2026-02-01cnbc.com

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

2026-01-30proactiveinvestors.co.uk

AstraZeneca obesity tie-up with CSPC seen as shrewd move

2026-01-30wsj.com

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

2026-01-30proactiveinvestors.co.uk

AstraZeneca strikes $1.2bn obesity drug deal with China's CSPC

2026-01-29reuters.com

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832
fillingDate 2025-11-06 2025-07-29 2024-09-30 2024-04-25 2024-02-08 2023-11-09 2023-06-30 2023-03-31 2022-09-30
acceptedDate 2025-11-06 07:36:27 2025-07-29 07:58:24 2025-02-18 16:06:30 2024-09-30 00:00:00 2024-04-25 06:26:55 2024-02-08 06:40:42 2023-12-30 19:00:00 2023-11-09 09:49:39 2023-06-30 00:00:00 2023-03-31 00:00:00 2022-12-30 19:00:00 2022-09-29 20:00:00 2021-12-30 19:00:00 2020-12-30 19:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 15 191M 14 457M 54 073M 13 565M 12 938M 12 679M 45 811M 11 492M 11 416M 10 879M 44 351M 10 982M 37 417M 26 617M
costOfRevenue 2 862M 2 473M 10 207M 3 081M 3 145M 3 143M 8 268M 2 095M 1 960M 1 905M 12 391M 2 982M 12 437M 5 299M
grossProfit 12 329M 11 984M 43 866M 10 484M 9 793M 9 536M 37 543M 9 397M 9 456M 8 974M 31 960M 8 000M 24 980M 21 318M
grossProfitRatio 0.812 0.829 0.773 0.757 0.752 0.818 0.828 0.825 0.728
researchAndDevelopmentExpenses 3 663M 3 548M 13 583M 3 115M 2 876M 2 699M 10 935M 2 584M 2 667M 2 611M 9 762M 2 357M 9 736M 5 991M
generalAndAdministrativeExpenses 4 972M 4 864M 19 669M 5 143M 4 929M 4 495M 17 683M 4 800M 0 0 17 448M 0 15 144M 0
sellingAndMarketingExpenses 148M 143M 555M 145M 132M 135M 539M 4 929M 5 117M 4 193M 536M 3 285M 446M 11 896M
sellingGeneralAndAdministrativeExpenses 5 120M 5 007M 20 224M 5 288M 5 061M 3 592M 18 222M 4 929M 5 117M 4 193M 17 984M 3 285M 15 590M 11 896M
otherExpenses -37M -79M 56M -25M -984M 0 193M 0 0 -138M 457M 949M -1 402M -1 731M
operatingExpenses 8 746M 8 476M 33 863M 8 378M 6 953M 6 291M 29 350M 7 443M 7 000M 6 666M 28 203M 6 591M 23 924M 16 156M
costAndExpenses 11 608M 10 949M 44 070M 11 459M 10 098M 9 434M 37 618M 9 538M 8 960M 8 571M 40 594M 9 573M 36 361M 21 455M
interestIncome 0 68M 345M 183M 100M 111M 301M 101M 64M 78M 81M 15M 43M 83M
interestExpense 349M 439M 1 682M 457M 443M 413M 1 589M 392M 431M 365M 1 330M 339M 1 276M 1 272M
depreciationAndAmortization 1 549M 1 389M 5 065M 1 817M 1 279M 1 255M 4 934M 1 282M 1 276M 1 339M 5 254M 1 348M 4 102M 2 896M
ebitda 5 142M 4 955M 15 438M 4 102M 4 125M 4 500M 13 422M 3 326M 2 519M 3 888M 9 085M 2 593M 5 113M 8 084M
ebitdaratio 0.338 0.343 0.302 0.319 0.355 0.289 0.221 0.357 0.236
operatingIncome 3 583M 3 508M 10 003M 2 106M 2 840M 3 245M 8 193M 1 954M 2 456M 2 549M 3 757M 1 245M 1 056M 5 162M
operatingIncomeRatio 0.236 0.243 0.155 0.22 0.256 0.17 0.215 0.234 0.113
totalOtherIncomeExpensesNet -339M -381M -1 312M -278M -443M -432M -1 294M -302M -368M -287M -1 256M -323M -1 321M -1 246M
incomeBeforeTax 3 244M 3 127M 8 691M 1 828M 2 397M 2 813M 6 899M 1 652M 2 088M 2 262M 2 501M 922M -265M 3 916M
incomeBeforeTaxRatio 0.214 0.216 0.135 0.185 0.222 0.144 0.183 0.208 0.084
incomeTaxExpense 709M 679M 1 650M 395M 469M 620M 938M 274M 268M 458M -792M -720M -380M 772M
netIncome 2 533M 2 450M 7 035M 1 429M 1 927M 2 179M 5 955M 1 374M 1 818M 1 803M 3 288M 1 640M 112M 3 196M
netIncomeRatio 0.167 0.169 0.105 0.149 0.172 0.12 0.159 0.166 0.149
eps 0.82 0.79 1.14 0.46 0.62 0.7 1.91 0.45 0.59 0.58 1.06 0.53 0.04 1.22
epsdiluted 0.81 0.79 0.46 0.62 0.7 0.44 0.59 0.58 0.53
weightedAverageShsOut 3 127M 3 100M 3 100M 3 100M 3 100M 3 098M 3 124M 3 098M 3 100M 3 098M 3 096M 3 096M 2 836M 2 624M
weightedAverageShsOutDil 3 122M 3 118M 3 126M 3 124M 3 120M 3 120M 3 124M 3 120M 3 120M 3 120M 3 120M 3 118M 2 854M 2 626M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-18 2023-12-31 2022-12-31 2021-12-31 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -1 337M -1 288M -1 249M -1 233M -1 189M
ebit 10 373M 8 488M 3 831M 1 011M 5 188M
nonOperatingIncomeExcludingInterest -370M -295M -74M 45M -26M
netIncomeFromContinuingOperations 7 041M 5 961M 3 293M 115M 3 144M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 7 035M 5 955M 3 288M 112M 3 196M
epsDiluted 1.13 1.91 1.06 0.04 1.22

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832
fillingDate 2025-11-06 2025-07-29 2024-09-30 2024-04-25 2024-02-08 2023-11-09 2023-06-30 2023-03-31 2022-09-30
acceptedDate 2025-11-06 07:36:27 2025-07-29 07:58:24 2025-02-18 16:06:30 2024-09-30 00:00:00 2024-04-25 06:26:55 2024-02-08 06:40:42 2024-02-20 16:32:15 2023-11-09 09:49:39 2023-06-30 00:00:00 2023-03-31 00:00:00 2023-02-21 16:45:44 2022-09-29 20:00:00 2022-02-22 17:13:16 2021-02-16 06:08:39
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 8 143M 7 058M 5 488M 4 797M 6 916M 7 841M 5 840M 4 871M 5 664M 6 232M 6 166M 4 458M 6 329M 7 832M
shortTermInvestments 39M 50M 37M 133M 160M 180M 20M 244M 148M 230M 77M 440M 69M 160M
cashAndShortTermInvestments 8 182M 7 108M 5 525M 4 930M 7 076M 8 021M 5 860M 5 115M 5 812M 6 462M 6 243M 4 898M 6 398M 7 992M
netReceivables 14 338M 14 168M 11 235M 0 11 047M 12 225M 8 407M 11 997M 0 0 9 192M 0 8 132M 5 651M
inventory 6 593M 6 467M 5 288M 5 662M 5 667M 5 337M 5 424M 5 292M 5 051M 4 967M 4 699M 5 078M 8 983M 4 024M
otherCurrentAssets 827M 1 196M 2 042M 13 563M 1 603M 11M 3 746M 97M 0 0 1 130M 10 248M 1 219M 142M
totalCurrentAssets 29 940M 28 939M 25 827M 24 155M 25 393M 25 594M 25 054M 22 501M 22 839M 22 266M 22 593M 20 224M 26 244M 19 544M
propertyPlantEquipmentNet 13 783M 13 229M 11 647M 11 513M 10 833M 10 616M 10 502M 9 700M 9 624M 9 599M 9 449M 9 227M 10 171M 8 917M
goodwill 21 219M 21 222M 21 025M 21 139M 21 060M 19 978M 20 048M 19 939M 19 960M 20 001M 19 820M 19 707M 19 997M 11 845M
intangibleAssets 38 191M 37 925M 37 177M 39 394M 39 426M 38 834M 38 089M 37 687M 38 326M 39 291M 39 307M 39 585M 42 387M 20 947M
goodwillAndIntangibleAssets 59 410M 59 147M 58 202M 60 533M 60 486M 58 812M 58 137M 57 626M 58 286M 59 292M 59 127M 59 292M 62 384M 32 792M
longTermInvestments 2 286M 4 851M 0 2 012M 2 894M 2 653M 1 777M 1 046M 995M 1 004M 0 662M 0 0
taxAssets 0 6 256M 5 347M 5 342M 4 734M 4 618M 0 4 057M 3 736M 3 498M 3 263M 3 436M 4 330M 3 438M
otherNonCurrentAssets 9 037M 0 3 012M 1 367M 0 0 5 649M 1 156M 1 063M 1 028M 2 051M 1 344M 2 234M 2 038M
totalNonCurrentAssets 84 516M 83 483M 78 208M 80 767M 78 947M 76 699M 76 065M 73 585M 73 704M 74 421M 73 890M 73 961M 79 119M 47 185M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 114 456M 112 422M 104 035M 104 922M 104 340M 102 293M 101 119M 96 086M 96 543M 96 687M 96 483M 94 185M 105 363M 66 729M
accountPayables 25 028M 23 986M 3 640M 21 684M 20 463M 19 699M 3 267M 20 542M 19 738M 19 210M 2 550M 17 694M 2 824M 2 350M
shortTermDebt 6 582M 6 853M 2 156M 1 570M 5 359M 6 331M 5 129M 5 607M 4 787M 3 857M 5 225M 5 618M 1 567M 2 194M
taxPayables 0 1 429M 1 807M 1 468M 1 525M 1 631M 2 076M 1 163M 1 200M 1 203M 1 364M 1 093M 1 379M 1 517M
deferredRevenue 0 0 0 0 1 525M 1 631M 0 0 0 0 0 0 0 0
otherCurrentLiabilities 2 444M 1 268M 17 313M 1 204M -306M 1 240M 6 132M 2 439M 1 850M 1 793M 14 999M 1 538M 14 936M 12 266M
totalCurrentLiabilities 34 054M 33 536M 27 866M 25 926M 28 566M 28 901M 30 542M 28 588M 26 375M 24 860M 26 293M 24 850M 22 594M 20 307M
longTermDebt 26 079M 25 986M 26 506M 29 992M 28 174M 27 259M 22 365M 22 969M 25 051M 27 646M 22 965M 23 681M 28 134M 17 505M
deferredRevenueNonCurrent 0 0 0 0 0 961M 7M 0 0 0 14M 0 26M 38M
deferredTaxLiabilitiesNonCurrent 0 3 615M 3 305M 3 568M 3 333M 2 621M 31M 2 752M 2 800M 2 795M 2 944M 3 479M 6 206M 2 918M
otherNonCurrentLiabilities 8 352M 4 475M 4 374M 4 631M 4 669M 5 050M 8 151M 4 556M 4 901M 5 575M 6 484M 10 869M 8 362M 9 834M
totalNonCurrentLiabilities 34 431M 34 076M 35 298M 38 191M 36 176M 35 891M 31 411M 30 277M 32 752M 36 016M 33 132M 34 181M 43 482M 30 784M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 1 758M 1 633M 1 452M 1 422M 1 241M 961M 1 128M 979M 953M 962M 953M 878M 987M 681M
totalLiabilities 68 485M 67 612M 63 164M 64 117M 64 742M 64 792M 61 953M 58 865M 59 127M 60 876M 59 425M 59 031M 66 076M 51 091M
preferredStock 0 0 0 0 0 0 949M 0 0 0 0 0 0 0
commonStock 388M 388M 388M 388M 388M 388M 388M 387M 387M 387M 387M 387M 387M 328M
retainedEarnings 8 213M 7 023M 3 160M 3 138M 1 847M -212M 4 516M -434M -234M -1 825M -574M -2 471M 1 710M 5 299M
accumulatedOtherComprehensiveIncomeLoss 2 044M 2 070M 0 0 2 078M 2 075M 0 2 078M 0 0 0 0 0 0
othertotalStockholdersEquity 35 243M 35 238M 37 193M 35 199M 35 194M 35 166M 37 239M 37 227M 37 218M
totalStockholdersEquity 45 888M 44 719M 40 786M 40 719M 39 512M 37 445M 39 143M 37 197M 37 392M 35 789M 37 037M 35 134M 39 268M 15 622M
totalEquity 45 971M 44 810M 40 871M 40 805M 39 598M 37 501M 39 166M 37 221M 37 416M 35 811M 37 058M 35 134M 39 287M 15 638M
totalLiabilitiesAndStockholdersEquity 114 456M 112 422M 104 922M 104 340M 102 293M 96 086M 96 543M 96 687M 94 165M
minorityInterest 83M 91M 85M 86M 86M 56M 23M 24M 24M 22M 21M 0 19M 16M
totalLiabilitiesAndTotalEquity 114 456M 112 422M 104 035M 104 922M 104 340M 102 293M 101 119M 96 086M 96 543M 96 687M 96 483M 94 165M 105 363M 66 729M
totalInvestments 2 325M 4 901M 37M 2 145M 3 054M 2 833M 1 797M 1 290M 1 143M 1 234M 77M 1 102M 69M 160M
totalDebt 32 661M 32 839M 30 114M 31 562M 33 533M 34 551M 28 622M 28 576M 29 838M 31 503M 29 143M 29 299M 30 688M 20 380M
netDebt 24 518M 25 781M 24 626M 26 765M 26 617M 26 710M 22 782M 23 705M 24 174M 25 271M 22 977M 24 841M 24 359M 12 548M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 8 302M 8 407M 7 212M 6 031M 3 806M
otherReceivables 2 933M 0 1 980M 2 101M 1 845M
prepaids 1 737M 1 617M 1 329M 1 512M 1 735M
totalPayables 8 058M 3 267M 5 841M 5 858M 5 655M
otherPayables 4 418M 0 3 291M 3 034M 3 305M
accruedExpenses 0 15 743M 0 0 0
capitalLeaseObligationsCurrent 339M 271M 228M 233M 192M
capitalLeaseObligationsNonCurrent 1 113M 857M 725M 754M 489M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 35 379M 35 188M 35 308M 35 279M 8 124M
otherTotalStockholdersEquity 1 859M -1 898M 1 916M 1 892M 1 871M

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN AZN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832 901 832
fillingDate 2025-11-06 2025-07-29 2024-09-30 2024-04-25 2024-02-08 2023-11-09 2023-06-30 2023-03-31 2022-09-30
acceptedDate 2025-11-06 07:36:27 2025-07-29 07:58:24 2025-02-18 16:06:30 2024-09-30 00:00:00 2024-04-25 06:26:55 2024-02-08 06:40:42 2024-02-20 16:32:15 2023-11-09 09:49:39 2023-06-30 00:00:00 2023-03-31 00:00:00 2023-02-21 16:45:44 2022-09-29 20:00:00 2022-02-22 17:13:16 2021-02-16 06:08:39
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 2 533M 3 127M 8 691M 1 828M 1 927M 2 179M 6 899M 1 652M 2 088M 2 262M 2 501M 923M -265M 3 916M
depreciationAndAmortization 1 549M 1 389M 5 065M 1 817M 1 279M 1 255M 4 934M 1 282M 1 276M 1 502M 5 480M 1 334M 6 530M 3 149M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 -619M 0 -615M -277M
stockBasedCompensation 0 0 0 0 0 0 579M 0 0 0 619M 0 615M 277M
changeInWorkingCapital 835M -345M -893M 41M -129M -455M 300M 897M -989M 242M 3 757M 1 067M 2 021M 361M
accountsReceivables 0 0 -1 624M 0 0 0 -1 425M 0 0 0 -1 349M 0 -961M -739M
inventory 0 0 -131M 0 0 0 -669M 0 0 0 3 941M 0 1 577M -621M
accountsPayables 0 0 0 0 0 0 1 425M 0 0 0 1 349M 0 961M 739M
otherWorkingCapital 835M -345M 862M 41M -129M -455M 969M 0 0 0 -184M 0 444M 982M
otherNonCashItems 217M -785M -1 002M -303M 8M 2 110M -2 367M -717M -657M -873M -1 930M -394M -2 323M -2 627M
netCashProvidedByOperatingActivities 5 134M 3 386M 11 861M 3 383M 3 085M 2 579M 10 345M 3 114M 1 718M 3 133M 9 808M 2 930M 5 963M 4 799M
investmentsInPropertyPlantAndEquipment -686M -659M -1 924M -417M -382M -1 605M -1 361M -879M -483M -1 470M -2 571M -1 111M -2 200M -2 606M
acquisitionsNet -328M -267M -3 927M -281M -2 297M -895M -1 179M -273M -184M -426M -1 061M -342M -9 433M -830M
purchasesOfInvestments 0 -188M -96M -29M -109M -98M -136M -95M -26M 0 -159M -321M -184M -119M
salesMaturitiesOfInvestments 0 114M 108M 47M 84M 17M 129M -68M 81M 19M 42M -2M 105M 2 126M
otherInvestingActivites -987M -1 108M -834M -168M 75M 94M 92M 631M 33M
netCashUsedForInvestingActivites -2 001M -2 108M -1 514M -2 872M -2 506M -1 221M -520M -1 246M -1 743M
debtRepayment -93M 632M -2 419M -1 134M -5 970M -1 247M -1 404M -2 004M -4M
commonStockIssued 0 1 000 000 -77M 5M 6M 4M 4M 4M 3M
commonStockRepurchased -19M 0 0 0 0 -833M 0 840M 0 -867M 0 0 0 0
dividendsPaid -1 611M -10M -1 576M -17M -3 033M -1 410M -22M -3 047M -1 393M
otherFinancingActivites -350M -105M -59M -76M -8M -913M -97M 3 883M -36M
netCashUsedProvidedByFinancingActivities -2 073M 518M -4 131M -1 222M 2 028M -2 726M -1 519M -2 031M -1 430M
effectOfForexChangesOnCash -12M 29M -93M 20M -6M -46M -60M -19M -36M -11M -80M -51M -62M 12M
netChangeInCash 1 048M 1 825M -208M -2 242M -1 015M 2 001M -346M -852M -357M -155M -55M -294M -1 508M 2 323M
cashAtEndOfPeriod 8 080M 7 032M 5 429M 4 435M 6 677M 7 841M 5 637M 4 619M 5 471M 5 828M 5 983M 4 186M 6 038M 7 546M
cashAtBeginningOfPeriod 7 032M 5 207M 5 637M 6 677M 7 692M 5 840M 5 983M 5 471M 5 828M 5 983M 6 038M 4 480M 7 546M 5 223M
operatingCashFlow 5 134M 3 386M 11 861M 3 383M 3 198M 2 579M 10 345M 3 114M 1 718M 3 133M 9 808M 2 930M 5 963M 4 799M
capitalExpenditure -686M -1 923M -4 586M -1 358M -668M -1 605M -3 778M -879M -483M -1 470M -2 571M -1 111M -2 200M -2 606M
freeCashFlow 4 448M 1 463M 7 275M 2 025M 2 530M 974M 6 567M 2 235M 1 235M 1 663M 7 237M 1 819M 3 763M 2 193M
link Link Link Link Link Link
finalLink Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -2 141M -1 517M 789M 654M 1 144M
netCashProvidedByInvestingActivities -7 980M -4 064M -2 960M -11 058M -285M
netDebtIssuance 1 809M -965M -1 197M 7 894M 1 647M
longTermNetDebtIssuance 1 840M -1 126M -1 271M 8 170M 1 359M
shortTermNetDebtIssuance -31M 161M 74M -276M 288M
netStockIssuance -43M 33M 29M 29M 30M
netCommonStockIssuance -43M 33M 29M 29M 30M
commonStockIssuance -43M 33M 29M 29M 30M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -4 629M -4 481M -4 364M -3 856M -3 572M
commonDividendsPaid -4 629M -4 481M -4 364M -3 856M -3 572M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -1 133M -1 154M -1 291M -418M -308M
netCashProvidedByFinancingActivities -3 996M -6 567M -6 823M 3 649M -2 203M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-06 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-08 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-07-28 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-09 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)

Press-releases

Show financial reports only

2026-06-02 12:00 ET
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
2026-06-01 12:00 ET
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
2026-05-29 01:18 ET
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
2026-05-22 14:16 ET
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
2026-05-22 11:00 ET
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
2026-05-18 ET
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
2026-05-15 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
2026-05-14 ET
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
2026-04-30 ET
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
2026-04-29 ET
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
2026-04-29 ET
AstraZeneca results: Q1 2026
2026-04-28 ET
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
2026-04-27 ET
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
2026-04-20 ET
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
2026-04-02 ET
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
2026-03-27 ET
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
2026-03-10 ET
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
2026-03-09 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
2026-02-20 12:00 ET
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
2026-02-13 12:00 ET
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
2026-02-11 14:00 ET
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
2026-02-10 12:00 ET
AstraZeneca results: FY and Q4 2025
2026-02-03 12:00 ET
DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
2026-02-02 ET
AstraZeneca begins trading on the New York Stock Exchange
2026-01-08 ET
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
2025-12-22 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
2025-12-15 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
2025-12-04 ET
Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement
2025-12-04 ET
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
2025-12-02 ET
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
2025-11-26 ET
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
2025-11-21 ET
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
2025-11-09 ET
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
2025-11-07 ET
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
2025-11-06 ET
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
2025-11-06 ET
AstraZeneca's 9M and Q3 2025 Financial Results
2025-10-19 ET
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
2025-10-18 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
2025-10-18 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
2025-10-17 ET
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
2025-10-17 ET
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
2025-10-17 ET
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
2025-10-15 ET
AstraZeneca unveils expanded manufacturing facility in Texas
2025-10-13 ET
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
2025-10-09 ET
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
2025-10-09 ET
Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
2025-10-07 ET
Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
2025-10-06 ET
DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
2025-09-29 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
2025-09-26 ET
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
2025-09-24 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
2025-09-22 ET
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
2025-09-18 ET
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
2025-09-17 ET
Advancing Cancer Research Brings New Hope for Patients Worldwide
2025-09-17 ET
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
2025-09-07 ET
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
2025-08-30 ET
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
2025-08-15 ET
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
2025-08-13 ET
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
2025-08-05 ET
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
2025-07-29 ET
AstraZeneca results: H1 and Q2 2025
2025-07-28 ET
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
2025-07-21 ET
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
2025-07-21 ET
TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer
2025-07-14 ET
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
2025-06-24 ET
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-02 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
2025-06-01 ET
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
2025-06-01 ET
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-05-29 ET
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
2025-05-27 ET
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
2025-05-21 ET
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
2025-05-20 ET
From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
2025-05-19 ET
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
2025-05-13 ET
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
2025-05-09 ET
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
2025-05-07 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
2025-05-05 ET
Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
2025-05-02 ET
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
2025-04-29 ET
AstraZeneca's Q1 2025 Financial Results
2025-04-28 ET
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
2025-04-23 ET
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
2025-04-21 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
2025-03-31 ET
​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
2025-03-31 ET
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
2025-03-26 ET
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
2025-03-25 ET
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
2025-03-17 ET
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
2025-03-17 ET
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
2025-03-14 ET
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
2025-03-07 ET
IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
2025-03-01 ET
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
2025-02-26 ET
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
2025-02-14 ET
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
2025-02-06 ET
AstraZeneca’s Full Year and Q4 2024 results
2025-01-27 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
2025-01-17 ET
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2025-01-17 ET
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
2025-01-13 ET
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-01-07 ET
Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC)
2024-12-12 ET
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
2024-12-11 ET
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
2024-12-09 ET
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2024-12-08 ET
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
2024-12-06 ET
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
2024-12-05 ET
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
2024-11-25 ET
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
2024-11-20 ET
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
2024-11-18 ET
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
2024-11-12 12:00 ET
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
2024-11-12 12:00 ET
AstraZeneca’s 9M and Q3 2024 results
2024-11-08 12:00 ET
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
2024-11-07 12:00 ET
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
2024-10-07 11:00 ET
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
2024-10-03 11:00 ET
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
2024-10-01 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
2024-09-26 11:00 ET
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
2024-09-23 11:00 ET
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2024-09-20 20:34 ET
FLUMIST approved for self-administration in the US
2024-09-18 11:00 ET
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
2024-09-16 11:00 ET
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
2024-09-15 14:30 ET
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
2024-09-09 17:50 ET
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
2024-09-08 16:25 ET
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
2024-09-03 11:00 ET
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
2024-08-16 11:00 ET
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
2024-08-15 11:00 ET
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
2024-07-29 11:00 ET
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
2024-07-25 11:00 ET
AstraZeneca’s H1 and Q2 2024 Financial Results
2024-06-25 11:00 ET
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
2024-06-17 11:00 ET
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
2024-06-16 11:00 ET
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
2024-06-12 21:35 ET
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
2024-06-11 10:00 ET
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
2024-06-10 11:00 ET
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
2024-06-06 11:00 ET
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
2024-06-05 12:00 ET
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
2024-06-04 11:00 ET
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
2024-06-02 18:32 ET
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
2024-06-02 12:05 ET
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
2024-06-02 12:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
2024-05-30 11:00 ET
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
2024-05-27 11:00 ET
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
2024-05-27 06:00 ET
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
2024-05-24 11:00 ET
AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting
2024-05-23 11:00 ET
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
2024-05-22 23:23 ET
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
2024-05-22 11:00 ET
AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
2024-05-21 06:00 ET
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
2024-05-21 06:00 ET
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
2024-05-19 21:17 ET
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
2024-05-08 12:12 ET
ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant
2024-05-02 11:00 ET
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
2024-05-01 11:05 ET
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
2024-04-29 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
2024-04-25 12:00 ET
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
2024-04-25 06:00 ET
Q1 2024 results
2024-04-24 14:52 ET
ANGLE partners with AstraZeneca in groundbreaking oncology contract
2024-04-16 12:00 ET
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
2024-04-16 12:00 ET
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
2024-04-16 11:00 ET
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
2024-04-11 11:00 ET
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
2024-04-06 03:10 ET
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
2024-04-06 01:43 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
2024-04-05 11:00 ET
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
2024-04-02 11:00 ET
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
2024-04-02 06:00 ET
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
2024-04-01 11:00 ET
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
2024-03-25 11:00 ET
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
2024-03-19 11:00 ET
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
2024-03-18 13:00 ET
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
2024-03-18 11:00 ET
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
2024-03-18 ET
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
2024-03-13 11:06 ET
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
2024-02-23 18:23 ET
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
2024-02-19 12:10 ET
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
2024-02-19 12:05 ET
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
2024-02-19 07:00 ET
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
2024-02-17 03:00 ET
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
2024-02-08 07:03 ET
AstraZeneca Full year and Q4 2023 Financial Results
2024-02-06 14:00 ET
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
2024-02-05 14:00 ET
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
2024-01-29 12:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
2024-01-22 12:00 ET
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
2024-01-19 15:05 ET
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
2024-01-05 08:00 ET
Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers
2024-01-02 14:00 ET
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
2023-12-22 00:13 ET
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
2023-12-11 00:35 ET
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
2023-12-06 21:01 ET
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
2023-11-30 13:00 ET
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
2023-11-29 12:00 ET
AstraZeneca advances scientific leadership in hematology at ASH 2023
2023-11-21 16:25 ET
Major Milestone Met in AI-Powered Fight Against Lung Cancer
2023-11-20 13:27 ET
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
2023-11-17 12:00 ET
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
2023-11-09 12:00 ET
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
2023-11-08 12:00 ET
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
2023-11-03 15:30 ET
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
2023-10-24 11:00 ET
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
2023-10-23 14:56 ET
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
2023-10-23 14:50 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
2023-10-23 14:30 ET
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2023-10-22 11:00 ET
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
2023-10-21 11:05 ET
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
2023-10-21 11:00 ET
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
2023-10-20 12:00 ET
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
2023-10-18 13:00 ET
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
2023-10-16 11:00 ET
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
2023-10-12 11:45 ET
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
2023-10-12 06:05 ET
AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
2023-10-11 11:00 ET
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
2023-10-10 14:30 ET
Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity
2023-09-22 11:00 ET
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
2023-09-22 06:00 ET
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
2023-09-14 06:00 ET
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
2023-09-11 16:58 ET
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
2023-09-11 11:05 ET
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
2023-09-11 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
2023-08-31 12:00 ET
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
2023-08-29 11:15 ET
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
2023-08-25 11:10 ET
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
2023-08-16 14:00 ET
AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
2023-07-27 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
2023-07-03 11:00 ET
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
2023-07-03 06:00 ET
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
2023-06-29 13:15 ET
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
2023-06-28 06:00 ET
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
2023-06-13 11:00 ET
AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
2023-06-12 11:00 ET
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
2023-06-05 12:05 ET
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
2023-06-05 12:00 ET
At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse
2023-06-05 12:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
2023-06-05 11:00 ET
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
2023-06-04 12:00 ET
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
2023-06-03 12:00 ET
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
2023-06-02 19:56 ET
IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
2023-06-01 11:00 ET
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
2023-05-30 12:04 ET
Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM
2023-05-26 11:00 ET
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
2023-05-25 11:00 ET
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
2023-05-23 18:15 ET
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
2023-05-17 11:00 ET
TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
2023-05-12 15:30 ET
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
2023-05-09 15:37 ET
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
2023-04-24 11:00 ET
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
2023-04-17 20:15 ET
Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
2023-04-17 20:00 ET
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023
2023-04-16 15:50 ET
IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
2023-04-14 07:10 ET
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy
2023-04-12 20:05 ET
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
2023-04-11 11:00 ET
AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023
2023-03-27 11:00 ET
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
2023-03-09 12:11 ET
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
2023-03-09 12:00 ET
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
2023-03-07 06:00 ET
Genomic Vision launches FiberSmart®, AI-powered software for automating genomic analysis
2023-03-06 12:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
2023-03-02 21:28 ET
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
2023-02-23 05:01 ET
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
2023-02-16 15:00 ET
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
2023-02-02 14:00 ET
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
2023-01-23 12:00 ET
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
2023-01-11 14:00 ET
AIRSUPRA™ (PT027) approved in the US for asthma
2023-01-05 14:30 ET
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
2023-01-05 06:00 ET
Genomic Vision Announces Successful Beta Testing of FiberSmart®
2022-12-13 15:02 ET
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
2022-12-08 13:35 ET
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
2022-12-08 13:30 ET
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
2022-12-07 13:30 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
2022-11-30 12:00 ET
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
2022-11-29 18:30 ET
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
2022-11-22 12:05 ET
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
2022-11-16 13:23 ET
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
2022-11-11 12:38 ET
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
2022-11-10 16:23 ET
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
2022-11-09 12:00 ET
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
2022-10-27 11:00 ET
ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
2022-10-26 11:05 ET
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
2022-10-26 11:00 ET
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
2022-10-24 11:12 ET
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
2022-10-20 13:00 ET
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
2022-10-12 11:00 ET
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
2022-10-03 11:15 ET
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
2022-09-16 11:10 ET
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
2022-09-15 16:00 ET
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
2022-09-12 15:05 ET
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
2022-09-11 13:35 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
2022-09-11 12:05 ET
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
2022-09-11 12:00 ET
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
2022-09-09 12:00 ET
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
2022-09-05 11:00 ET
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
2022-08-27 14:59 ET
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
2022-08-27 14:36 ET
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
2022-08-24 11:00 ET
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
2022-08-16 11:00 ET
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
2022-08-12 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
2022-08-08 11:00 ET
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
2022-08-08 10:01 ET
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
2022-08-06 00:06 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
2022-08-05 18:20 ET
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
2022-07-25 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
2022-07-01 13:00 ET
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
2022-06-30 11:00 ET
IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
2022-06-23 12:35 ET
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
2022-06-21 11:05 ET
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
2022-06-21 11:00 ET
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
2022-06-13 12:00 ET
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
2022-06-05 12:10 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
2022-06-04 14:00 ET
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
2022-06-02 13:00 ET
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
2022-05-27 13:00 ET
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
2022-05-23 11:00 ET
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
2022-05-16 09:00 ET
Proteros Expands Oncology Collaboration and License Agreement with AstraZeneca
2022-05-15 17:24 ET
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
2022-05-13 20:21 ET
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer
2022-05-12 13:00 ET
AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicines to Patients
2022-05-05 11:05 ET
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
2022-05-05 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
2022-05-05 11:00 ET
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
2022-05-04 12:00 ET
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
2022-04-28 11:00 ET
ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
2022-04-27 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
2022-04-27 01:00 ET
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
2022-04-25 12:00 ET
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
2022-04-19 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
2022-04-18 12:03 ET
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
2022-04-07 01:09 ET
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
2022-04-04 17:54 ET
PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness
2022-03-24 11:00 ET
AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees
2022-03-16 17:30 ET
LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
2022-03-12 00:53 ET
LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
2022-03-07 04:30 ET
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
2022-03-01 13:30 ET
BioMark Provides the Third Quarter Operational Update and 2022 Outlook
2022-02-21 16:15 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer
2022-02-14 22:00 ET
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
2022-02-14 10:56 ET
Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in Colombia
2022-01-24 12:10 ET
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
2022-01-18 22:50 ET
IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
2022-01-18 22:20 ET
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
2022-01-17 12:00 ET
CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
2022-01-13 12:05 ET
AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU
2022-01-13 12:00 ET
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
2022-01-10 21:30 ET
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development
2021-12-23 12:00 ET
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
2021-12-16 14:58 ET
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
2021-12-15 06:30 ET
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
2021-12-14 00:55 ET
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
2021-12-12 15:00 ET
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
2021-12-09 15:05 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
2021-12-09 00:37 ET
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
2021-12-03 12:00 ET
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
2021-11-30 13:30 ET
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
2021-11-30 03:00 ET
Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
2021-11-25 11:00 ET
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
2021-11-24 09:00 ET
Inaugural Asia Summit on Global Health opens today
2021-11-24 00:00 ET
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
2021-11-19 15:00 ET
Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics
2021-11-18 13:00 ET
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
2021-11-17 15:03 ET
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
2021-11-17 09:00 ET
Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
2021-11-05 11:00 ET
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
2021-11-03 13:00 ET
American Kidney Fund Announces Major Support from AstraZeneca to Address Health Equity in Kidney Disease
2021-11-03 12:00 ET
Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics
2021-11-02 11:00 ET
SAGA Diagnostics enters into an assay development agreement with AstraZeneca
2021-11-01 11:00 ET
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
2021-10-25 20:21 ET
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
2021-10-20 13:00 ET
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
2021-10-15 11:00 ET
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
2021-10-08 11:00 ET
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
2021-10-05 11:00 ET
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
2021-10-04 11:00 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
2021-09-29 11:00 ET
AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
2021-09-27 11:00 ET
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
2021-09-24 10:45 ET
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
2021-09-18 15:30 ET
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
2021-09-18 13:05 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
2021-09-18 11:30 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
2021-09-17 16:05 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
2021-09-17 11:30 ET
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
2021-09-09 15:00 ET
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
2021-09-09 11:00 ET
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
2021-08-31 11:00 ET
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
2021-08-20 11:00 ET
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
2021-08-18 07:15 ET
Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic
2021-08-10 09:01 ET
My Green Lab Certification Named as Critical Indicator of Progress in the United Nations' 2030 Breakthroughs Emissions
2021-08-05 20:05 ET
 Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
2021-08-02 11:00 ET
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
2021-07-13 06:00 ET
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
2021-07-09 13:00 ET
EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration
2021-07-08 12:00 ET
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
2021-07-08 11:00 ET
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
2021-06-25 16:09 ET
Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
2021-06-08 13:30 ET
PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021
2021-06-02 09:00 ET
Proteros Enters Into Oncology Collaboration and License Agreement With AstraZeneca
2021-05-19 21:05 ET
AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
2021-05-13 11:00 ET
New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
2021-05-10 13:00 ET
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
2021-05-05 08:00 ET
Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study
2021-04-27 14:00 ET
Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center
2021-04-20 14:01 ET
Reify Health Powers Patient Recruitment and Enrollment Across AstraZeneca’s Extensive Breast Cancer Clinical Trial Pipeline
2021-04-20 08:01 ET
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
2021-04-06 11:00 ET
AstraZeneca Announces Collaboration with Massachusetts General Hospital to Accelerate Digital Health Solutions
2021-03-25 00:53 ET
AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy
2021-03-22 11:00 ET
AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis
2021-02-16 14:00 ET
/C O R R E C T I O N -- AliveCor/
2021-02-16 07:00 ET
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) AUTHORISED IN THE UK FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
2021-01-12 14:00 ET
Recombinetics Inc. Announces Neurofibromatosis Type 1 Research Collaboration with AstraZeneca
2021-01-11 21:01 ET
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
2020-12-12 12:48 ET
AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development
2020-11-02 12:00 ET
Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
2020-09-19 17:04 ET
TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
2020-09-18 11:00 ET
LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
2020-09-18 11:00 ET
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years
2020-09-15 11:03 ET
AstraZeneca Selects Veeva Vault Quality Suite to Modernize Global Quality Management
2020-09-08 10:31 ET
Biopharma Leaders Unite to Stand With Science
2020-08-31 20:53 ET
Development of COVID-19 Vaccine AZD1222 Expands Into US Phase III Clinical Trial Across All Adult Age Groups
2020-08-30 15:02 ET
FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial
2020-08-21 07:00 ET
RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease
2020-08-13 11:30 ET
AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season
2020-08-11 11:30 ET
AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Same
2020-08-06 12:00 ET
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
2020-07-30 13:47 ET
TAGRISSO Granted Breakthrough Therapy Designation in the US for the Adjuvant Treatment of Patients With Stage IB-IIIA EGFR-mutated Lung Cancer
2020-07-28 11:00 ET
FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Patients With Chronic Kidney Disease
2020-07-27 06:00 ET
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
2020-07-24 12:10 ET
BREZTRI AEROSPHERE approved in the US for the maintenance treatment of COPD
2020-07-16 12:12 ET
FARXIGA Granted Fast Track Designation in the US for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design
2020-07-16 11:00 ET
BRILINTA Significantly Reduced the Rate of the Composite of Stroke and Death in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack in the Phase III THALES Trial
2020-07-15 11:30 ET
Bob Harper and AstraZeneca Bring Virtual Series to Heart Attack Survivors to Inspire Others with Stories About Second Chances
2020-07-09 11:00 ET
BRILINTA Granted FDA Priority Review for the Reduction of Subsequent Stroke in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack
2019-02-14 14:00 ET
Tanabe Research Labs Announce FDA Acceptance of its IND Application for TR1801-ADC (MT-8633), an ADC Targeting cMet Positive Solid Tumors
2019-01-28 16:00 ET
UPMC Health Plan Announces Innovative, Value-Based Agreement with AstraZeneca

SEC forms

Show financial reports only

SEC form 6
2026-06-15 10:52 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-06-01 14:10 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-06-01 14:06 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-29 10:43 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-27 10:04 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-26 11:17 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-26 11:09 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-26 11:02 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-18 14:15 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-18 13:42 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-18 13:36 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-14 11:25 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-01 14:23 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-01 12:45 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-05-01 12:40 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-29 11:23 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-28 11:31 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-27 10:29 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-23 10:10 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-21 10:19 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-20 11:03 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-09 17:01 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-02 13:27 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-04-01 14:30 ET
AstraZeneca PLC published news for 2026 q1
SEC form 6
2026-03-31 11:48 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-27 12:04 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-20 11:59 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-16 12:45 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-10 12:07 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-10 11:37 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-06 13:11 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-06 12:50 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-06 12:43 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 21:05 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-03-02 17:00 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-26 08:59 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-25 10:40 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 20
2026-02-24 16:17 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-24 16:06 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-24 06:51 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-24 06:45 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-20 06:57 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-10 11:55 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-03 12:01 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-02 18:26 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-02 12:51 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-02-02 12:25 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-01-30 11:19 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-01-29 08:08 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-01-20 12:18 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-01-08 11:04 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2026-01-02 12:24 ET
AstraZeneca PLC published news for 2025 q4
SEC form 6
2025-12-22 12:47 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-22 12:18 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-22 12:02 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-19 08:35 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-16 11:42 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-16 11:19 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-04 18:48 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-01 16:47 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-12-01 16:40 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-26 11:27 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-24 11:54 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-20 13:31 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-17 17:52 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-14 10:12 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-10 12:15 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-06 07:36 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-03 18:31 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-03 18:22 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-03 17:36 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-11-03 17:36 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-28 14:10 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-28 12:02 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-22 12:07 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-20 11:12 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-20 10:47 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-14 10:05 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-07 10:30 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-06 11:18 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-10-01 14:19 ET
AstraZeneca PLC published news for 2025 q3
SEC form 6
2025-09-29 11:05 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-29 10:59 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-29 10:08 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-25 17:27 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-22 11:46 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-22 11:39 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-17 11:46 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-17 11:11 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-09-02 10:17 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-28 15:14 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-26 17:22 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-21 14:51 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-18 15:07 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-15 14:40 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-12 14:45 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-08-01 18:32 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-29 11:58 ET
AstraZeneca PLC reported for 2025 q2
SEC form 6
2025-07-24 17:09 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-22 10:33 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-16 10:49 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-14 14:30 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-07 10:24 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-07-01 15:34 ET
AstraZeneca PLC published news for 2025 q2
SEC form 6
2025-06-24 10:59 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-06-13 16:03 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-06-12 14:46 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-06-06 11:52 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-06-02 17:13 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-06-02 17:03 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-27 10:09 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-23 12:56 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-21 13:41 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-20 11:20 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-09 15:23 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-07 13:53 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-06 13:15 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-02 13:38 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-01 17:07 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-05-01 15:44 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-29 17:07 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-29 16:38 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-29 16:22 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-22 10:37 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-11 17:40 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-04 10:43 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-04 10:06 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-04-01 16:30 ET
AstraZeneca PLC published news for 2025 q1
SEC form 6
2025-03-31 11:16 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-31 11:11 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-21 12:32 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-17 11:30 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-17 11:23 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-17 11:17 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-12 19:33 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-07 15:23 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-07 12:20 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-07 12:17 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-07 11:31 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-06 16:06 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-05 15:52 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-03 15:22 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-03-03 11:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-28 14:29 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-26 11:08 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-19 11:59 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-18 21:01 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-18 15:30 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-18 13:02 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-18 12:49 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 20
2025-02-18 00:00 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-06 09:53 ET
AstraZeneca PLC reported for 2024 q4
SEC form 6
2025-02-03 13:05 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-02-03 06:23 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2025-01-28 14:25 ET
AstraZeneca PLC published news for 2024 q4
SEC form 6
2024-12-05 06:00 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-12-04 09:01 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-12-02 10:35 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-12-02 10:28 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-25 06:43 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-20 11:15 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-18 06:11 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-15 09:13 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-15 06:48 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-13 12:31 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-12 07:54 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-12 07:50 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-12 07:38 ET
AstraZeneca PLC reported for 2024 q3
SEC form 6
2024-11-12 07:10 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-08 09:10 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-11-01 11:46 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-10-21 09:48 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-10-07 06:38 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-10-01 10:45 ET
AstraZeneca PLC published news for 2024 q3
SEC form 6
2024-09-26 06:42 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-23 06:44 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-23 06:27 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-20 13:34 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-18 06:21 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-13 10:50 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-09-03 06:05 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-07-26 06:42 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-07-25 09:06 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-07-15 06:15 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-07-01 10:07 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-07-01 06:07 ET
AstraZeneca PLC published news for 2024 q2
SEC form 6
2024-06-26 17:00 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-26 17:00 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-25 06:12 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-25 06:07 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-18 06:38 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-17 06:21 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-12 10:14 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-04 16:23 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-03 10:29 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-03 10:23 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-06-03 06:35 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-28 06:15 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-21 06:08 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-20 06:32 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-16 06:41 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-15 10:09 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-07 07:31 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-02 06:49 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-05-01 10:26 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-29 07:18 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-29 06:52 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-25 06:26 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-11 13:22 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-11 06:55 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-08 06:14 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-05 06:22 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-02 13:22 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-02 08:45 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-04-02 07:54 ET
AstraZeneca PLC published news for 2024 q1
SEC form 6
2024-03-25 07:28 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-19 06:02 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-14 07:12 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-12 07:29 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-07 06:34 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-07 06:30 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-06 10:11 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-06 10:06 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-04 06:33 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-03-01 10:39 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC reported for 2023 q4
SEC form 6
2024-02-26 16:05 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-26 06:19 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-22 09:19 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-22 09:14 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-22 06:08 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-21 06:04 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 16:22 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 09:25 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 07:49 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 07:12 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 06:52 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 06:47 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-20 06:27 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 20
2024-02-20 00:00 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-08 06:40 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-02-01 10:30 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-01-19 08:31 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2024-01-02 10:53 ET
AstraZeneca PLC published news for 2023 q4
SEC form 6
2023-12-27 07:09 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-12-26 17:25 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-11-09 10:05 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-11-09 10:01 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-11-09 09:57 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-11-09 09:49 ET
AstraZeneca PLC reported for 2023 q3
SEC form 6
2023-11-01 12:24 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-11-01 06:38 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-10-03 07:36 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-10-02 10:27 ET
AstraZeneca PLC published news for 2023 q3
SEC form 6
2023-09-25 12:49 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-09-20 06:55 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-09-15 11:00 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-09-11 11:07 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-09-06 06:59 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-09-01 10:20 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-07-28 08:46 ET
AstraZeneca PLC reported for 2023 q2
SEC form 6
2023-07-28 06:25 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-07-17 14:08 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-07-03 13:35 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-07-03 08:30 ET
AstraZeneca PLC published news for 2023 q2
SEC form 6
2023-06-28 17:28 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-09 06:38 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-09 06:21 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-02 12:12 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-01 12:07 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-01 12:00 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-06-01 06:36 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-05-26 06:18 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-05-22 06:53 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-05-17 06:43 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-05-09 06:56 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-05-09 06:46 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-04-05 06:19 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-04-03 13:53 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-04-03 07:51 ET
AstraZeneca PLC published news for 2023 q1
SEC form 6
2023-03-30 08:11 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-27 06:28 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-22 07:28 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-22 07:04 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-09 06:30 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-08 06:38 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-08 06:26 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-06 06:07 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-03 16:32 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-01 11:52 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-03-01 06:49 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-24 13:34 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-24 09:05 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-24 06:37 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-23 06:05 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-22 06:10 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-21 16:59 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-21 16:45 ET
AstraZeneca PLC reported for 2022 q4
SEC form 6
2023-02-21 08:24 ET
AstraZeneca PLC published news for 2022 q4
SEC form 20
2023-02-21 00:00 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-13 09:21 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-13 09:13 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-09 08:48 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-02-01 11:23 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-01-26 13:42 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-01-17 10:25 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-01-11 08:57 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-01-09 08:15 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2023-01-03 11:08 ET
AstraZeneca PLC published news for 2022 q4
SEC form 6
2022-12-30 07:12 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-28 06:43 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-28 06:25 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-21 06:36 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-21 06:22 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-19 08:49 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-19 08:23 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-19 07:04 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-19 06:52 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-19 06:42 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-15 06:32 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-08 09:17 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-01 11:14 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-12-01 11:05 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-30 06:05 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-29 06:46 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-23 10:40 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-14 06:58 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-14 06:58 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-14 06:54 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-14 06:07 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-10 07:00 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-09 06:41 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-04 08:50 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-11-01 11:54 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-10-26 07:15 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-10-25 06:31 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-10-24 07:01 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-10-03 11:55 ET
AstraZeneca PLC published news for 2022 q3
SEC form 6
2022-09-30 06:24 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-27 06:05 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-27 06:00 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-23 06:01 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-22 06:48 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-21 06:18 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-20 06:15 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-16 06:50 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-16 06:40 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-16 06:30 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-06 06:13 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-06 06:05 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-09-01 11:22 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-30 08:58 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-30 06:22 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-30 06:11 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-25 06:46 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-25 06:31 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-25 06:15 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-16 06:17 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-15 12:40 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-12 06:36 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-11 07:38 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-08 06:37 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-04 06:02 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-01 13:16 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-01 11:18 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-08-01 11:09 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-29 06:18 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-29 00:00 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-25 08:43 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-25 06:51 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-25 06:24 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-19 06:05 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-05 06:11 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-07-01 10:00 ET
AstraZeneca PLC published news for 2022 q2
SEC form 6
2022-06-30 06:27 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-28 21:23 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-27 07:57 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-27 07:44 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-21 06:24 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-06 07:23 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-01 10:47 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-06-01 10:18 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-20 11:26 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-09 09:25 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-06 11:45 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-05 07:00 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-05 06:47 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-05 06:40 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-04 06:07 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-05-03 10:28 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-29 14:02 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-29 06:59 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-29 06:39 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-28 06:11 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-27 06:31 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-25 06:25 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-19 06:40 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-04-01 10:30 ET
AstraZeneca PLC published news for 2022 q1
SEC form 6
2022-03-29 06:27 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-28 08:31 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-25 14:06 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-24 14:12 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-24 07:20 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-23 09:38 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-23 07:24 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-17 06:11 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-14 11:07 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-14 10:11 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-09 13:16 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-07 11:46 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-01 12:22 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-01 12:07 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-03-01 06:55 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-23 06:05 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-22 17:13 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-22 08:10 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-22 07:28 ET
AstraZeneca PLC published news for 2021 q4
SEC form 20
2022-02-22 00:00 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-16 06:12 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-15 06:13 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-11 11:45 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-10 06:15 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-02-01 10:56 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-19 07:32 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-19 06:59 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-18 06:28 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-07 06:07 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-05 06:10 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2022-01-04 11:10 ET
AstraZeneca PLC published news for 2021 q4
SEC form 6
2021-12-29 06:35 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-21 07:27 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-20 07:01 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-20 06:46 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-15 10:15 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-09 08:16 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-07 06:26 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-01 12:02 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-12-01 10:53 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-11-30 07:47 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-11-15 11:28 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-11-12 09:30 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-11-01 12:43 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-11-01 07:41 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-25 06:08 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-18 09:38 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-15 07:13 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-12 09:16 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-04 07:09 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-10-01 11:02 ET
AstraZeneca PLC published news for 2021 q3
SEC form 6
2021-09-30 15:15 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-29 08:28 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-28 06:21 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-24 06:19 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-23 07:03 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-23 06:40 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-21 06:54 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-20 06:38 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-09 11:16 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-09 07:43 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-03 06:18 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-09-01 12:28 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-26 06:30 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-26 06:22 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-20 06:31 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-20 06:20 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-16 10:44 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-11 10:49 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-09 07:41 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-09 07:31 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-02 10:41 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-08-02 06:23 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-30 07:39 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-30 00:00 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-26 06:15 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-22 08:15 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-21 16:16 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-21 12:09 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-21 11:54 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-21 09:52 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-19 06:23 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-16 06:13 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-14 06:30 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-08 06:05 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-06 06:50 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-07-01 11:20 ET
AstraZeneca PLC published news for 2021 q2
SEC form 6
2021-06-29 10:56 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-28 07:05 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-28 06:50 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-24 07:17 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-23 06:45 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-22 07:21 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-15 06:05 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-07 06:19 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-04 06:27 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-04 06:22 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-02 06:24 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-01 12:28 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-06-01 11:54 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-28 16:15 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-28 06:06 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-27 06:40 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-26 07:16 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-26 06:06 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-25 06:46 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-24 08:18 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-21 06:23 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-18 11:41 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-11 10:20 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-11 10:00 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-07 06:28 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-04 13:43 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-05-04 08:19 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-30 07:21 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-26 07:12 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-26 07:05 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-26 06:59 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-16 08:15 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-14 06:23 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-12 12:07 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-12 12:07 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-12 07:14 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-04-01 11:17 ET
AstraZeneca PLC published news for 2021 q1
SEC form 6
2021-03-30 08:19 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-30 07:21 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-25 13:49 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-25 11:23 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-22 08:14 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-16 07:19 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-16 07:11 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-09 11:15 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-04 10:54 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-03 06:31 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-02 07:28 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-03-01 10:43 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-22 06:22 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-17 06:33 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-16 07:11 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-16 07:01 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-16 06:40 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-16 06:08 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-11 06:48 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-11 06:42 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-10 06:38 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-05 06:56 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-04 07:52 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-01 10:20 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-01 08:48 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-02-01 06:24 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-29 11:07 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-26 12:22 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-26 06:33 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-25 06:21 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-25 06:15 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-20 06:20 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-19 06:05 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-15 07:30 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-06 06:27 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-04 10:48 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2021-01-04 06:36 ET
AstraZeneca PLC published news for 2020 q4
SEC form 6
2020-12-30 07:29 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-29 07:01 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-21 06:52 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-21 06:15 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-17 11:40 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-16 16:33 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-15 06:06 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-14 06:32 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-14 06:17 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-14 06:10 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-01 11:53 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-01 11:50 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-12-01 07:25 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-30 06:59 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-23 06:17 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-20 06:09 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-10 06:54 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-09 06:11 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-06 06:29 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-05 08:54 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-05 06:51 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-05 06:44 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-05 06:33 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-11-02 12:06 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-30 06:44 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-29 07:45 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-28 06:16 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-28 06:08 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-20 07:20 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-19 07:27 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-19 07:21 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-13 06:02 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-02 06:28 ET
AstraZeneca PLC published news for 2020 q3
SEC form 6
2020-10-01 11:05 ET
AstraZeneca PLC published news for 2020 q3